PROTOCOL Open Access



The sequelae of hematopoietic stem cell transplantation in adolescents and young adults: protocol for a systematic review

Nikita V. Baclig^{1*}, Antonia Osuna-Garcia², Vivek Chotai³, Patricia A. Ganz⁴ and Eden R. Brauer⁵

Abstract

Background Hematopoietic stem cell transplantation (HSCT) is a life-saving treatment for adolescents and young adults (ages 15–39) with hematologic malignancy. Given the significant developmental milestones usually achieved during this unique life stage, this population is especially vulnerable to the interruption caused by a cancer diagnosis and its treatment. HSCT is a particularly invasive form of cancer therapy with many negative physical, social, and psychological sequelae. The long-term impact of HSCT in adolescents and young adults with hematologic malignancies warrants a systematic investigation of its effects to best shape clinical care and health policy.

Methods This protocol for a systematic review will focus on the long-term physical, psychological, social, spiritual, and health behavior effects experienced by adolescents and young adults who undergo HSCT for hematologic malignancy. We have constructed a specific search strategy that queries these five domains, which will be applied to five databases—Embase, PubMed, Cochrane Trials and Reviews, PsychInfo, and CINAHL—to identify the key literature. Two independent reviewers will perform a title/abstract screen followed by a full-text screen using standard screening templates to ensure the inclusion of outcomes in the post-acute HSCT period. Risk of bias will be assessed using the University of Adelaide Joanna Briggs Institute Collaboration Critical Appraisal Tools. Data from included studies will be abstracted on study characteristics, study setting, sample characteristics, and outcomes. Given the broad scope of the research question, data synthesis will focus on qualitative methods in accordance with Institute of Medicine standards.

Discussion While adolescents and young adults undergoing hematopoietic stem cell transplantation for hematologic malignancy are understood to have a unique survivorship experience, the sequelae of this treatment approach in this population have not been previously aggregated. This systematic review intends to expand insight into the adolescent and young adult experiences with HSCT in order to inform age-appropriate survivorship care and deliver this life-saving intervention with the best possible outcomes.

Systematic review registration PROSPERO CRD42022361663

Keywords Adolescent and young adult, Hematopoietic stem cell transplantation, Survivorship

*Correspondence: Nikita V. Baclig NBaclig@mednet.ucla.edu Full list of author information is available at the end of the article



Baclig et al. Systematic Reviews (2024) 13:156 Page 2 of 8

Background

Hematopoietic stem cell transplantation (HSCT) is a life-saving procedure for hematologic malignancies. However, it is associated with significant physical and mental hardship, causing a wide array of challenges in survivorship. Survivors frequently endorse fatigue and sleep disruption [1], psychiatric diagnoses such as depression and post-traumatic stress disorder (PTSD) [2, 3], fear of cancer recurrence [4], sexual dysfunction [5], and overall poor quality of life [6, 7].

Adolescent and young adult cancer patients are those diagnosed between age 15 and 39 years, according to the National Cancer Institute [8]. This group is particularly vulnerable to the life interruption that is caused by diagnosis and treatment. Having cancer as an AYA increases the risk of chronic physical conditions, subsequent cancers, and premature death [9]. Furthermore, AYAs with cancer often face disruptions in education and career trajectories as well as significant financial hardship [10, 11]. A systematic review from Barnett and colleagues summarized a wide array of issues for AYA cancer survivors including greater incidence of risky health behaviors, impaired fertility, body image distortion, psychosexual dysfunction, mental health symptoms, challenges to social well-being, and limited survivorship care [12].

While the most common AYA cancers—thyroid, breast, melanoma, and testicular—are not frequent indications for HSCT, the population of AYAs who are candidates for HSCT is considerable. New cases of Hodgkin lymphoma, leukemia, and non-Hodgkin lymphoma are diagnosed in 3.4, 3.6, and 4.0 per 100,000 individuals ages 15–39 years, respectively [13]. Reports from the Center for International Blood and Marrow Transplant Research (CIBMTR) suggest that the number of AYAs who undergo HSCT is growing, with nearly 3000 transplants in 2019, and that the most common indication for HSCT in AYAs remains hematologic malignancy, specifically acute myeloid leukemia (AML), Hodgkin lymphoma, and acute lymphoblastic leukemia (ALL) [14]. Furthermore, while the 5-year survival rates for AYAs with these malignancies are improving, they continue to be lower than those for children (ages 0-14), who generally have the best outcomes [15]. Among those who die in the post-acute transplant period (> 100 days), primary causes are generally not directly disease-related [14]. Thus, the population of AYA HSCT survivors is growing, yet they remain at risk for poor clinical outcomes in the survivorship period driven by non-cancer complications of their care. There remains significant equipoise in the literature about whether this risk is driven by physical, psychosocial, health behavior, or some combination of these factors.

The regular successful use of HSCT, arguably the most intensive cancer treatment available, to treat hematologic malignancies in the AYA population has resulted in a population of young cancer survivors with unique and significant sequelae. A rapid rise in the number of publications addressing these effects has increased awareness of the challenges this group faces, yet these findings have not been systematically indexed. Reviews from Mehta [16], Tewari [17], and others have initiated this investigation; however, none has addressed more recent findings in the literature, and all retain a focus on the physical consequences of HSCT in AYAs. Given that AYAs who undergo HSCT experience life interruption at a crucial moment in development, the psychosocial ramifications are noteworthy [18-20]. Here, we present a protocol for a systematic review of the literature addressing both the physical and non-physical sequelae of HSCT among AYA patients with hematologic malignancy.

This systematic review will address the long-term physical, psychological, social, spiritual, and health behavior effects of hematopoietic stem cell transplant for AYAs who undergo HSCT for hematologic malignancy. To define these concepts, we draw from models presented in two seminal texts: the Institute of Medicine's "lost in transition" report [21] and an Institute of Medicine workshop addressing specific AYA patient needs [22]. Figure 1 shows the depictions of these original survivorship models, the first of which can be originally attributed to Ferrell and colleagues [23]. In this review, we coalesce these models into a single framework (Fig. 2) that conceptualizes the effects of HSCT among AYAs within five major domains: physical effects, psychological wellbeing, social well-being, spiritual well-being, and health behaviors. The primary aim of this review is to synthesize the known evidence describing the impact of HSCT among AYAs in order to identify avenues for further research and improved survivorship care in this unique population.

Methods

This systematic review protocol was developed in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines [24]. The systematic review will include reports of original research published in English and indexed in online databases up to February 28, 2023. Unpublished manuscripts, conference abstracts, case studies, case-series reports, and articles without full-text manuscript availability will not be included. Studies will be drawn from a wide array of online databases to cover the literature from multiple scientific disciplines. Searches will be conducted in Embase, PubMed, Cochrane Trials and

Baclig et al. Systematic Reviews (2024) 13:156 Page 3 of 8




Fig. 1 Established conceptual models. From these models, our conceptual framework (Fig. 2) was developed. **a** Quality of life: conceptual model, published in from Cancer Patient to Cancer Survivor:Lost in Transition [21]. **b** Life disruptions for adolescent and young adult (AYA) cancer patients, published in summary of the Institute of Medicine and Livestrong Foundation Workshop [22]

	PHYSICAL EFFECTS	PSYCHOLOGICAL WELLBEING	SOCIAL WELLBEING	SPIRITUAL WELLBEING	HEALTH BEHAVIORS
Concepts	 Fatigue Sleep Pain Fertility & Family Building Sexual function Cognitive Impairment Late effects 	Emotions Self-esteem Body image Psychological Distress/Burden Depression Anxiety Post-traumatic stress and growth Isolation/Loneliness Suicidality and Self-harm Fear of recurrence Control Cognition and attention	Family dynamics Intimate partner relations Peer relations (including fellow survivors) Relationships with informal caregivers Independence/ independent living Return to school, work Educational attainment Post-treatment employment/career outcomes	Trust in health Meaning of illness Religiosity Uncertainty Resilience End of life care	Insurance coverage Care context and transitions Communication Financial burden, toxicity, hardship Health promotion Diet & Nutrition Physical activity Risky sexual behaviors Substance Use

Fig. 2 Conceptual Framework for Systematic Review. Captures the five main domains of anticipated sequelae of hematopoietic stem cell transplantation in adolescents and young adults with hematologic malignancies

Reviews, PsychInfo, and CINAHL. Additional papers will be identified by hand review of the included articles' bibliographies.

Our focus will be on patients who received a diagnosis of hematologic malignancy between the ages of 15–39 years and subsequently underwent HSCT. Survivors of malignancies treated in childhood or in older adulthood will be excluded. Studies will only be included if data is stratified by age at cancer diagnosis or if the study is limited to AYA patients. Similarly, we are interested in recipients of HSCT for hematologic malignancies, so AYA patients who received HSCT for other

indications (i.e., for breast cancer, testicular cancer, or benign hematologic conditions) will be excluded. As our research question focuses on long-term survivorship and the risk of death from acute complications of HSCT is highest in the first 100 days, we will exclude studies that only describe the effects during the first 100 days post-transplant [25]. Studies will be included if the outcomes reported incorporate at least one of the conceptual domains described above. Notably, we will include both positive and negative outcomes of HSCT, as both fit within the defined domains.

Baclig et al. Systematic Reviews (2024) 13:156 Page 4 of 8

PubMed

((("hematopoietic cell"[Title/Abstract] OR "haematopoietic cell"[Title/Abstract] OR "hematopoietic stem cell"[Title/Abstract] OR "haematopoietic stem cell"[Title/Abstract] OR "bone marrow"[Title/Abstract]) AND "transplant*"[Title/Abstract]) OR HCT[Title/Abstract] OR "Hematopoietic Stem Cell Transplant*"[Title/Abstract] OR "blood cancer*"[Title/Abstract] OR (Hemato*[Title/Abstract] AND (neoplasm*[Title/Abstract] OR malign*[Title/Abstract] OR cancer[Title/Abstract])) OR "Hematopoietic Stem Cell Transplantation"[Mesh] OR "Bone Marrow Transplantation"[Mesh] OR "Hematologic Neoplasms"[Mesh])

AND

("adolescen*"[Title/Abstract] OR "young adults"[Title/Abstract] OR "young adult"[Title/Abstract] OR "younger adults"[Title/Abstract] OR "teen*"[Title/Abstract])

AND

("surviv*"[Title/Abstract] OR "late effects"[Title/Abstract] OR "late effect"[Title/Abstract] OR "longitudinal"[Title/Abstract] OR "long term"[Title/Abstract] OR "follow-up"[Title/Abstract] OR "remission"[Title/Abstract] OR "sequelae"[Title/Abstract] OR "post treatment"[Title/Abstract] OR "Long Term Adverse Effects" [MeSH Terms] OR (("patient*" [Title/Abstract]) AND ("experience*"[Title/Abstract]) AND ("psychosocial"[Title/Abstract] OR "psycholog*"[Title/Abstract] OR "psychiatric"[Title/Abstract] OR "mental"[Title/Abstract] OR "socio*"[Title/Abstract] OR "quality of life"[Title/Abstract] OR "survivorship"[Title/Abstract] OR "caregiver*"[Title/Abstract] OR "wellbeing"[Title/Abstract] OR "well being"[Title/Abstract] OR "activities of daily living"[Title/Abstract] OR "activities of daily life"[Title/Abstract] OR "normalcy"[Title/Abstract] OR "health status"[Title/Abstract] OR "Return to Work"[Title/Abstract] OR "education*"[Title/Abstract] OR "school"[Title/Abstract] OR "neurocognitive"[Title/Abstract] OR "cognitive"[Title/Abstract] OR "employment"[Title/Abstract] OR "financial strain"[Title/Abstract] OR "financial burden"[Title/Abstract] OR "financial hardship"[Title/Abstract] OR "medical debt"[Title/Abstract] OR "medical bankruptcy"[Title/Abstract] OR "insurance"[Title/Abstract] OR "friends" [Title/Abstract] OR "interpersonal relationships" [Title/Abstract] OR "Social Support"[Title/Abstract] OR "peer support"[Title/Abstract] OR "romantic"[Title/Abstract] OR "intimate"[Title/Abstract] OR "Fertility"[Title/Abstract] OR "reproductive"[Title/Abstract] OR "emotion*"[Title/Abstract] OR "Depressive Disorder"[Title/Abstract] OR "depression"[Title/Abstract] OR "anxiety"[Title/Abstract] OR "post-traumatic"[Title/Abstract] OR "resilience" [Title/Abstract] OR "psychology" [MeSH Subheading] OR "Sociological Factors" [MeSH Terms] OR "quality of life" [MeSH Terms] OR "caregivers" [MeSH Terms] OR "self care"[MeSH Terms] OR "activities of daily living"[MeSH Terms] OR "Return to Work"[MeSH Terms] OR "Educational Status" [MeSH Terms] OR "employment" [MeSH Terms] OR "financing, personal"[MeSH Terms] OR "friends"[MeSH Terms] OR "Interpersonal Relations"[MeSH Terms] OR "Social Support" [MeSH Terms] OR "Social Adjustment" [MeSH Terms] OR "Fertility Preservation" [MeSH Terms] OR "Fertility" [MeSH Terms] OR "Mental Health" [MeSH Terms] OR "emotions"[MeSH Terms] OR "stress, psychological"[MeSH Terms] OR "Depressive Disorder"[MeSH Terms] OR "depression"[MeSH Terms] OR "Anxiety Disorders"[MeSH Terms] OR "anxiety" [MeSH Terms] OR "stress disorders, post traumatic" [MeSH Terms] OR "resilience, psychological"[MeSH Terms] OR "adaptation, psychological"[MeSH Terms] OR ("distress"[Title/Abstract] AND ("psychological"[Title/Abstract] OR "existential"[Title/Abstract])) OR "Religion and psychology" [MeSH Terms] OR "spiritual" [Title/Abstract] OR "religious"[Title/Abstract] OR "Health Behavior"[MeSH Terms] OR "physical activity"[Title/Abstract] OR "smoking"[MeSH Terms] OR "smoking"[Title/Abstract] OR "Risk-Taking"[MeSH Terms] OR "Sexual Behavior"[MeSH Terms] OR "sexual partner"[Title/Abstract] OR "sexual partners" [Title/Abstract] OR "sexual function" [Title/Abstract] OR "sexual dysfunction"[Title/Abstract] OR "Self-Injurious Behavior"[MeSH Terms] OR "Substance-Related Disorders"[MeSH Terms] OR "recreational drugs"[Title/Abstract] OR "drinking"[Title/Abstract] OR "alcohol" [Title/Abstract] OR "Drug use" [Title/Abstract] OR "substance abuse"[Title/Abstract] OR "fear of recurrence"[Title/Abstract] OR "poor sleep"[Title/Abstract] OR "self-image" [Title/Abstract] OR "identity" [Title/Abstract])))

NOT ("Animals"[Mesh] NOT "Humans"[Mesh])

Fig. 3 Search strategy. Example of literature search strategy for PubMed. Strategies for other databases were designed to reflect the content of the PubMed search

Baclig et al. Systematic Reviews (2024) 13:156 Page 5 of 8


In collaboration with colleagues in the UCLA Louise M. Darling Biomedical Library, a finalized search strategy was developed based on the five survivorship domains and created to maximize both inclusivity and discernment around this unique research question. The final search strategy will encompass the concepts of "cancer" or "hematopoietic stem cell transplantation" and "adolescents and young adults" and "survivorship". Please see Fig. 3 for an example of a complete search for PubMed. The search strategy will be translated as appropriate for all databases investigated.

All search results will be managed using Rayyan Intelligent Systematic Review [26]. Search results from individual databases will be uploaded directly into Rayyan, and duplicates will be removed before screening. All screening decisions will be recorded according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (see Fig. 4). Screening of search results will commence with initial title/abstract screening by two independent, blinded reviewers. Regular reviewer meetings will be held, at first to identify points of clarification in screening protocols and then to discuss and settle any conflicting screening decisions. Inter-rater reliability will be calculated from the majority of screened articles, once the screening protocol has been tested and established. Any disagreements that cannot be resolved

will be evaluated by a third reviewer. The decision rationale for each article reviewed will be documented.

Articles that fail to be excluded by pre-determined criteria at this stage or articles for which more information is needed will move to a second, full-text screening stage. In the full-text stage, complete manuscripts will be attached to Rayyan entries for more in-depth review. Once again, two independent, blinded reviewers will conduct full-text screening according to established criteria. Inter-rater reliability will be calculated for the totality of full-text reviews. The decision rationale for each publication will again be documented. With regular meetings, we will attempt to reach a consensus should disagreement about inclusion arise. However, should consensus not be achieved, a third blinded reviewer will be incorporated.

Critical appraisal will then be assessed for each study included after full-text screening. University of Adelaide JBI Collaboration Critical Appraisal Tools will be used for critical appraisal and risk of bias assessment [28]. JBI tools were selected over others (such as ROB-INS-I or CASP) primarily because we anticipate studies addressing this topic to be widely varied in study design and the JBI tools offer checklists tailored for different study structures. For each study, we will identify which checklist most appropriately reflects the design of the



*Consider, if feasible to do so, reporting the number of records identified from each database or register searched (rather than the total number across all databases/registers).
**If automation tools were used, indicate how many records were excluded by a human and how many were excluded by automation tools.

Fig. 4 Proposed flow diagram. Derived from PRISMA 2020 flow diagram for new systematic reviews [27]

Baclig et al. Systematic Reviews (2024) 13:156 Page 6 of 8

study and both reviewers will independently evaluate. Inter-rater reliability will be calculated. Studies will be included if > 70% of responses to checklist criteria are "yes". If the two reviewers' assessments are discordant, a third reviewer will assess. Should any study not have an appropriate checklist for risk of bias assessment using the JBI tools, it will be included to encompass as much of the literature as possible. Such articles will be marked as having not been assessed for bias.

Once articles for inclusion are finalized, data extraction will be performed independently by two reviewers. A detailed abstraction guide will be drafted, piloted, and adapted if needed to ensure standardized responses from all reviewers. Data will then be abstracted directly into a structured evidence table, with abstracted data

blinded to other reviewers until the time of the joint review. Abstracted data will be jointly reviewed at regular intervals, and any discrepancies will be discussed until a resolution is reached. Data variables and outcomes to be abstracted are listed in Table 1. Given the nature of this review, outcomes will vary by article but will address at least one of the concepts included in the five domains of our conceptual framework (see Fig. 2). There will be no prioritization of outcomes as articles addressing any concept will be included in our qualitative review. Both first-order constructs (rates, distributions, proportions, direct study subject quotes) as well as second-order constructs (author interpretations, conclusions, or ideas) will be included as study outcomes.

Table 1 Data variables for extraction and their definitions

Category	Variable	Definition
Publication specifications	Author(s)	First and last names of all authors
	Date	Date of initial publication
	Publication ID	PMID, doi, and/or ISSN
	Journal	Name of journal where originally published
	Database	Database source(s) from which the article was identified
Study characteristics	Design	Study design as defined by Campbell and Stanley (citation)
	Aim	Objective of the study or primary research question it attempts to answer
	Intervention	Exposure or treatment whose effect is being studied
	Comparison	Defined group to whom the intervention is being compared, if applicable
	Inclusion criteria	Subject characteristics necessary to be included in the study
	Exclusion criteria	Subject characteristics that prevented inclusion in the study
	Data source	Type of data that was collected and analyzed in the study (i.e., medical records, insurance databases, survey responses)
	Study instruments	List any standardized scientific instruments used (i.e., PHQ-9 to measure depression)
	Analysis	Planned statistical analysis described by study authors
Study setting	Location	Physical context for the study including facility (i.e., hospital vs. clinic) and geographic location (city, state, country)
	Time	Period of time in which data was collected including start and end dates
	Population	Larger group from which study subjects selected
Sample characteristics	Size	Number of subjects included in the study
	Percentage AYA	Percentage of study subjects who were between 15 and 39 years old at the time of study inclusion
	Age at diagnosis	Average age of cancer diagnosis among study subjects
	Age at HSCT	Average age of HSCT among study subjects
	Male sex	Percentage of study subjects who were male
	Race/ethnicity	Distribution of races/ethnicities among study subjects
	Insurance	Distribution of insurance coverage status among study subjects
	Malignancy	Distribution of patients with leukemia, Hodgkin lymphoma, and non-Hodgkin lymphoma
	Conditioning regimen	Distribution of various conditioning regimens used for HSCT
Outcomes	Primary outcome	The main finding of the study
	Secondary outcomes	Additional study findings
	Domain addressed	Which of the following conceptual domains were addressed in study outcomes: physical, psychological, social, spiritual, and health behaviors
	Strengths	Author reported the strengths of the study
	Limitations	Author reported the limitations of the study

Baclig et al. Systematic Reviews (2024) 13:156 Page 7 of 8

While data synthesis often involves both qualitative and quantitative analysis [29], we anticipate that the wide scope of this review will result in outcomes that cannot feasibly be quantitatively synthesized. Thus, we will focus primarily on qualitative synthesis. Data abstracted into evidence tables will be coalesced into summary tables by domain. In accordance with the Institute of Medicine standards for qualitative analysis [30], we will focus our synthesis on a descriptive review of the clinical and methodological characteristics of included studies, emphasizing strengths, limitations, and how bias could compromise the reported results. We will also identify patterns in findings across studies and examine how individual study characteristics impact these common themes and summative deductions. Meta-bias will be assessed across studies with attention to publication bias specifically. Finally, we will discuss the relevance of the included studies to our population of interest, identifying the gaps in the literature and opportunities for further study. Given the nature of the data, we will similarly forego formal assessment of confidence in cumulative data as tools such as the Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Any major protocol amendments will be documented and resubmitted for review.

Discussion

While AYA patients who received HSCT for hematologic malignancy are understood to have a unique survivorship experience, the sequelae of transplantation in this population have not been previously aggregated. As a result, there are limitations to further research and clinical innovation for this population. This systematic review intends to expand our insight into AYA experiences with HSCT to deliver this life-saving intervention with the best possible outcome.

Abbreviations

AYAs Adolescents and young adults

HSCT Hematopoietic stem cell transplantation

PTSD Post-traumatic stress disorder

UCLA University of California in Los Angeles

Acknowledgements

Bethany Myers, a UCLA Health & Life Sciences librarian, contributed significantly to the development of the online database search strategy.

Authors' contributions

NVB contributed to the conceptualization of the protocol, protocol design, plan for data extraction and synthesis, and drafted the work. AOG contributed to the conceptualization of the protocol and protocol design. VC contributed to the conceptualization, review, and revision of the protocol. PAG contributed to the conceptualization and substantively revised the protocol. ERB contributed to the conceptualization of the protocol, protocol design, plan for data extraction and synthesis, and substantively revised the protocol.

Funding

There was no funding support or sponsorship for the development of this protocol.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave., CHS 60-054, Los Angeles, CA 90095, USA. ²UCLA Louise M. Darling Biomedical Library, 12-077 Center for Health Sciences, Los Angeles, CA 90095-1798, USA. ³University of California Los Angeles, Los Angeles, CA 90095, USA. ⁴UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA, 650 Charles Young Drive South, Room A2-125 CHS, Los Angeles, CA 90095-6900, USA. ⁵UCLA School of Nursing, 700 Tiverton Drive, Factor Bldg. Room 4-234, Los Angeles, CA 90095-6900, USA.

Received: 10 August 2023 Accepted: 13 May 2024 Published online: 14 June 2024

References

- Bevans M, El-Jawahri A, Tierney DK, Wiener L, Wood WA, Hoodin F, et al. National institutes of health hematopoietic cell transplantation late effects initiative: the patient-centered outcomes working group report. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2017;23(4):538–51.
- Nakamura ZM, Nash RP, Quillen LJ, Richardson DR, McCall RC, Park EM. Psychiatric care in hematopoietic stem cell transplantation. Psychosomatics. 2019;60(3):227–37.
- Amonoo HL, Massey CN, Freedman ME, El-Jawahri A, Vitagliano HL, Pirl WF, et al. Psychological considerations in hematopoietic stem cell transplantation. Psychosomatics. 2019;60(4):331–42.
- Andrykowski M, Cordova M, Hann D, Jacobsen P, Fields K, Phillips G. Patients' psychosocial concerns following stem cell transplantation. Bone Marrow Transplant. 1999;24(10):1121–9.
- Li Z, Mewawalla P, Stratton P, Yong ASM, Shaw BE, Hashmi S, et al. Sexual health in hematopoietic stem cell transplant recipients. Cancer. 2015;121(23):4124–31.
- Bush NE, Donaldson GW, Haberman MH, Dacanay R, Sullivan KM. Conditional and unconditional estimation of multidimensional quality of life after hematopoietic stem cell transplantation: a longitudinal follow-up of 415 patients. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2000;6(5A):576–91.
- Norkin M, Hsu JW, Wingard JR. Quality of life, social challenges, and psychosocial support for long-term survivors after allogeneic hematopoietic stem-cell transplantation. Semin Hematol. 2012;49(1):104–9.
- ayao_prg_report_2006_final.pdf. Available from: https://www.livestrong. org/sites/default/files/what-we-do/reports/ayao_prg_report_2006_final. pdf. Cited 2021 Oct 23.
- Ryder-Burbidge C, Diaz RL, Barr RD, Gupta S, Nathan PC, McKillop SJ, et al. The burden of late effects and related risk factors in adolescent and young adult cancer survivors: a scoping review. Cancers. 2021;13(19):4870.
- Parsons SK, Lerner D, Rodday AM, Curtis R, Kelly K, Conti R, et al. Parental work limitations at diagnosis of advanced stage pediatric Hodgkin lymphoma - results of caregiver work limitations questionnaire (CG WLQ).

Baclig et al. Systematic Reviews

(2024) 13:156

- J Clin Oncol. 2018;36(15). Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L625969919&from=export.
- Husson O, Huijgens PC, van der Graaf WTA. Psychosocial challenges and health-related quality of life of adolescents and young adults with hematologic malignancies. Blood. 2018;132(4):385–92.
- Barnett M, McDonnell G, DeRosa A, Schuler T, Philip E, Peterson L, et al. Psychosocial outcomes and interventions among cancer survivors diagnosed during adolescence and young adulthood (AYA): a systematic review. J Cancer Surviv Res Pract. 2016;10(5):814–31.
- SEER. Cancer among adolescents and young adults (AYAs) cancer stat facts. Available from: https://seer.cancer.gov/statfacts/html/aya.html. Cited 2021 Nov 30.
- Phelan R, Chen M, Bupp C, Bolon YT, Broglie L, Brunner-Grady J, et al. Updated trends in hematopoietic cell transplantation in the United States with an additional focus on adolescent and young adult transplantation activity and outcomes. Transplant Cell Ther Off Publ Am Soc Transplant Cell Ther. 2022;28(7):409.e1-409.e10.
- Theresa H, Keegan M, et al. Survival trends among adolescents and young adults diagnosed with cancer in the United States: Comparisons with children and older adults. JCO. 2024;42;630–41. https://doi.org/10. 1200/ICO 23.01367
- Mehta PA, Rotz SJ, Majhail NS. Unique challenges of hematopoietic cell transplantation in adolescent and young adults with hematologic malignancies. Biol Blood Marrow Transplant. 2018;24(12):e11–9.
- Tewari P, Franklin AR, Tarek N, Askins MA, Mofield S, Kebriaei P. Hematopoietic stem cell transplantation in adolescents and young adults. Acta Haematol. 2014:132(3–4):313–25.
- Pulewka K, Strauss B, Hochhaus A, Hilgendorf I. Clinical, social, and psycho-oncological needs of adolescents and young adults (AYA) versus older patients following hematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2021;147(4):1239–46.
- Cooke L, Chung C, Grant M. Psychosocial care for adolescent and young adult hematopoietic cell transplant patients. J Psychosoc Oncol. 2011;29(4):394–414.
- Nikita V. Baclig, et al. Mental health symptom severity and health care utilization in adolescent and young adult cancer survivors. JCO. 2022;40:229. https://doi.org/10.1200/JCO.2022.40.28_suppl.229.
- Institute of Medicine and National Research Council. From Cancer Patient to Cancer Survivor: Lost in Transition. Washington, DC: The National Academies Press; 2006. https://doi.org/10.17226/11468.
- Nass SJ, Beaupin LK, Demark-Wahnefried W, Fasciano K, Ganz PA, Hayes-Lattin B, et al. Identifying and addressing the needs of adolescents and young adults with cancer: summary of an Institute of Medicine workshop. Oncologist. 2015;20(2):186–95.
- Ferrell BR, Dow KH, Grant M. Measurement of the quality of life in cancer survivors. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 1995;4(6):523–31.
- Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
- Styczyński J, Tridello G, Koster L, Iacobelli S, van Biezen A, van der Werf S, et al. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors. Bone Marrow Transplant. 2020;55(1):126–36.
- Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. https://doi. org/10.1186/s13643-016-0384-4.
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. The BMJ. Available from: https://www.bmj.com/content/ 372/bmj.n71. Cited 2023 Jul 28.
- 28. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and incidence data. Int J Evid Based Healthc. 2015;13(3):147–53.
- Nelson HD. Systematic reviews to answer health care questions. Philadelphia: Wolters Kluwer Health; 2014. p. 230.
- Institute of Medicine (US) Committee on Standards for Systematic Reviews of Comparative Effectiveness Research. Finding what works in health care: standards for systematic reviews. In: Eden J, Levit L, Berg A, Morton S, editors. Washington (DC): National Academies Press (US); 2011.

Available from: http://www.ncbi.nlm.nih.gov/books/NBK209518/. Cited 2023 Jul 27.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.